Abstract: Objective The objective of this study was to detect the expressions of Galectin-9(Gal-9)and CD8 in osteosarcoma tissues, analyze the relationship between their expression and the clinical pathological features of osteosarcoma, and explore the impact on prognosis. Methods This study included 58 patients with initial diagnosis, surgical resection, and postoperative pathological confirmation of osteosarcoma from 2006 to 2016, and collected their clinical and pathological data. The expression of Gal-9 and CD8 was detected and the disease-free survival(DFS)and overall survival(OS)of osteosarcoma patients were statistically analyzed. Results The immunohistochemical results revealed that Gal-9 was low expressed in 47 cases(81.0%)and highly expressed in 11 cases(19.0%);CD8 was low expressed in 28 cases(48.3%)and highly expressed in 30 cases(51.7%). The high expression group of Gal-9 showed a significantly increase in tumor diameter compared to the low expression group(P＜0.05). Compared with the high expression group, the low expression group of CD8 significantly shortened DFS(P＜0.05). The group with low expression of Gal-9 and high expression of CD8(n=24)had a significantly higher proportion of women, shorter tumor diameter, and longer DFS and OS(P＜0.05). Multivariate Cox analysis showed that low expression of Gal-9 and high expression of CD8 were independent prognostic factors affecting DFS and OS in patients with osteosarcoma(P＜0.05). Conclusion Low expression of Gal-9 and high expression of CD8 in osteosarcoma patients indicate a better prognosis, which can provide a basis for prognostic stratification and selection of immunotherapy targets in osteosarcoma patients.

Key words: Osteosarcoma, Galectin-9, CD8, Prognosis